



Medicine Supply Notification

MSN/2025/010

Desmopressin 10microgram/dose nasal spray

Tier 2 – medium impact*

Date of issue: 03/03/2025

Link: [Medicines Supply Tool](#)

Summary

- Desmopressin 10microgram/dose nasal spray is out of stock with an anticipated re-supply date of early September 2025.
- Unlicensed supplies of desmopressin 10microgram/dose nasal spray are available, lead times may vary.
- Desmopressin 100 and 200microgram tablets, desmopressin sublingual tablets and DDAVP Melt oral lyophilisates (60, 120 and 240microgram) remain available and can support an increase in demand (see Supporting information).
- Desmopressin 4microgram/ml injection is available and can support an increase in demand (see Supporting information).

Actions Required

Where patients have insufficient supply of desmopressin 10microgram/dose nasal spray until the resupply date, clinicians should:

- consider prescribing unlicensed imports of desmopressin 10microgram/dose nasal spray (see Supporting information); or
- if the above option cannot be sourced in time or is not considered suitable, prescribe an equivalent dose of an oral desmopressin product, ensuring patients are counselled on the change in formulation, and dosage (see Supporting information); and
- If the above options are not considered appropriate, advice should be sought from specialists on an alternative management option.

The switch from the nasal to an oral formulation should be overseen by the endocrinology team.

Supporting information

Desmopressin is a synthetic form of Antidiuretic Hormone (ADH) used to treat cranial diabetes insipidus (Arginine Vasopressin Deficiency, AVP-D) and is considered a life sustaining medication in this situation. A [patient safety alert](#) was issued by NHS England in 2016 to raise awareness of the risk of severe dehydration and death caused by an omission or delay of desmopressin in patients with cranial diabetes insipidus. The main themes from reported incidents of desmopressin omission, included: a lack of awareness of the critical nature of desmopressin amongst medical, pharmacy and nursing staff; and poor availability of desmopressin within inpatient clinical areas.

Desmopressin nasal spray is licensed for the treatment of vasopressin-sensitive central diabetes insipidus and as a diagnostic test of the renal concentrating capacity.

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

Dose of desmopressin preparations for diabetes insipidus

	Nasal spray	Tablet*	Oral lyophilisate/ sublingual*
Dose	10 to 20 micrograms daily. In cases of insufficient efficacy dose can be increased on a case-by-case basis up to 40 micrograms in adults divided into 2 doses of 20 micrograms, and to 20 micrograms in children and adolescents (<18 years) divided into 2 doses of 10 micrograms	Starting dose in adults and children is 100 micrograms three times daily, adjusted in accordance with patient's response. For majority, maintenance dose is 100 to 200 micrograms three times daily	Starting dose in adults and children is 60 micrograms three times daily, adjusted in accordance with patient's response. For majority, maintenance dose is 60 to 120 micrograms three times daily.

*As not all oral desmopressin products are licensed for diabetes insipidus, and they may differ in excipients, individual SmPCs should be consulted.

Switching between desmopressin products

Individual dose titration based on patient's response is required as intranasal desmopressin is more potent than oral formulations and differs in dosing interval. Selection of a dose should be determined by the endocrinology team.

Desmopressin Injection

This is licensed to establish renal concentration capacity.

Links to further information

[SmPC Desmopressin 10microgram/dose nasal spray](#)

[SmPC Desmopressin oral lyophilisates](#)

[SmPC Desmopressin 100microgram tablets](#)

[SmPC Desmopressin 200microgram tablets](#)

[SmPC Desmopressin sublingual tablets](#)

[SmPC Desmopressin injection](#)

[BNF Desmopressin](#)

[NHSE Patient Safety Alert: Risk of severe harm or death when desmopressin is omitted or delayed in patients with cranial diabetes insipidus](#)

[Arginine Vasopressin Deficiency \(Diabetes Insipidus\) | Society for Endocrinology.](#)

Guidance on ordering and prescribing unlicensed imports

The following specialist importers have confirmed they can source unlicensed desmopressin 10microgram/dose nasal spray (please note there may be other companies that can also source supplies):

- Alium medical
- Durbin
- Genetech
- Mawdsleys

Any decision to prescribe an unlicensed medicine must consider the relevant guidance and NHS Trust or local governance procedures. Unlicensed imports do not undergo any central quality assessment or suitability evaluation. Therefore, any import must be locally assessed in line with local unlicensed medicines processes.

Please see the links below for further information:

- [The supply of unlicensed medicinal products](#), Medicines and Healthcare products Regulatory Agency (MHRA)
- [Professional Guidance for the Procurement and Supply of Specials](#), Royal Pharmaceutical Society

- [Prescribing unlicensed medicines](#), General Medical Council (GMC),

When prescribing a product that is not licensed in the UK due to a supply issue with the licensed alternative prescribers must indicate on the FP10 prescription that an unlicensed product is required. This can be done in one of the following two ways:

Electronic prescriptions – if the required unlicensed product is shown on electronic prescribing systems, GPs should select:

- Desmopressin 10microgram/dose nasal spray (imported)

Paper prescriptions – where the unlicensed product is not shown on electronic prescribing systems, GPs should use a paper prescription and annotate with the following wording: “**special order**”.

Enquiries

Enquiries from NHS Trusts in England should in the first instance be directed to your Specialist Pharmacy Service Regional Pharmacy Procurement Team, who will escalate to national teams if required.

REGION	Lead RPPS	Email	Associate RPPS	Email
Midlands	Andi Swain	andi.swain@nhs.net	Dav Manku	Dav.Manku@uhb.nhs.uk
East of England	James Kent	james.kent@nhs.net	Tracy McMillan	tracy.mcmillan2@nhs.net
London	Jackie Eastwood	j.eastwood@nhs.net	Daniel Johnson	Daniel.Johnson@nhs.net
North East and Yorkshire	David Allwood	davidallwood@nhs.net	Penny Daynes	penny.daynes@nhs.net
North West	Richard Bateman	richard.bateman@liverpoolft.nhs.uk	Andy Stewart	Andrew.stewart@liverpoolft.nhs.uk
South East	Alison Ashman	Alison.Ashman@berkshire.nhs.uk	Melanie Renney	melanie.renney@berkshire.nhs.uk
South West	Danny Palmer	danny.palmer@uhbw.nhs.uk	Natalie Bryson	Natalie.Bryson@uhbw.nhs.uk

Scotland

nss.nhssmedicineshortages@nhs.scot

Wales

MedicinesShortages@gov.wales

Northern Ireland

RPHPAdmin@northerntrust.hscni.net

All other organisations should send enquiries about this notice to the DHSC Medicine Supply Team quoting reference number MSN2025/010

Email: DHSCmedicinesupplyteam@dhsc.gov.uk.